# Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

> **NCT04222335** · NA · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Toulouse** · enrollment: 80 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **OTHER:** Blood samples

## Key facts

- **NCT ID:** NCT04222335
- **Lead sponsor:** University Hospital, Toulouse
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-26
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04222335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04222335, "Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04222335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*